Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash from Investing Activities: 2016-2024

Historic Cash from Investing Activities for Whitehawk Therapeutics (WHWK) over the last 9 years, with Dec 2024 value amounting to $25.2 million.

  • Whitehawk Therapeutics' Cash from Investing Activities fell 1901.91% to -$91.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year decrease of 47.97%. This contributed to the annual value of $25.2 million for FY2024, which is 69.71% down from last year.
  • According to the latest figures from FY2024, Whitehawk Therapeutics' Cash from Investing Activities is $25.2 million, which was down 69.71% from $83.2 million recorded in FY2023.
  • Over the past 5 years, Whitehawk Therapeutics' Cash from Investing Activities peaked at $83.2 million during FY2023, and registered a low of -$132.9 million during FY2022.
  • Moreover, its 3-year median value for Cash from Investing Activities was $25.2 million (2024), whereas its average is -$8.2 million.
  • Per our database at Business Quant, Whitehawk Therapeutics' Cash from Investing Activities surged by 132,310.25% in 2021 and then tumbled by 628.31% in 2022.
  • Whitehawk Therapeutics' Cash from Investing Activities (Yearly) stood at -$19,025 in 2020, then surged by 132,310.25% to $25.2 million in 2021, then crashed by 628.31% to -$132.9 million in 2022, then spiked by 162.61% to $83.2 million in 2023, then tumbled by 69.71% to $25.2 million in 2024.